
1 Supplementary Data


2 Clinical trial design and primary clinical outcomes

3 We conducted a single-arm, open-label Phase II clinical trial: the DARANA study (Dynamics of Androgen 4 Receptor Genomics and Transcriptomics After Neoadjuvant Androgen Ablation; NCT03297385). In this 5 study, 56 men with primary high-risk (Gleason score \geq 7) PCa were enrolled. Mean age at inclusion was 6 67 years, baseline serum PSA 12.8 ng/mL and the majority of patients had an ISUP2 (28%) or ISUP4 (36%) 7 PCa (Fig. 1A; Table 1). Prior to ENZ therapy, magnetic resonance imaging (MRI)-guided core needle tumor 8 biopsies were taken. Subsequently, patients received neoadjuvant ENZ treatment (160 mg/day) for three 9 months without androgen deprivation therapy. 55 patients completed therapy without dose adjustments, 10 while one patient (DAR37) discontinued ENZ three weeks prematurely. All patients underwent a robotic-11 assisted laparoscopic prostatectomy (RALP). Based on baseline MRI information and palpation, additional 12 tumor-targeted core needle biopsies were taken ex vivo. 30% of prostatectomy specimens had positive 13 surgical margins, which was comparable to 1492 non-treated historical controls with Gleason ≥7 (34%; see 14 methods) and analogous to a previous neoadjuvant study on ENZ alone versus ENZ in combination with 15 the 5α -reductase inhibitor dutasteride and androgen deprivation therapy in high-risk patients for 6 months, 16 describing 26.1% positive margins in the triple-therapy arm (1). No differences in pre and post treatment T-17 stages were observed. A higher incidence of ypN1 lymph nodes than cN1 lymph nodes was possibly due 18 to differences in accuracy of radiographic pre-treatment assessments versus post-treatment histological 19 assessments. After a mean follow-up of 37 months, the mean time to biochemical recurrence was 12 20 months (Supplementary Fig. S1A; Supplementary Table S1).

Supplementary Figure S1




B The DARANA study: sample flow diagram



22

23 Figure S1: The DARANA study.

(A) Kaplan-Meier curve showing the biochemical recurrence (BCR)-free survival of the DARANA cohort, treated with 3
months of neoadjuvant ENZ prior to prostatectomy. BCR was defined as a rise in Prostate-specific antigen (PSA)
serum levels of ≥ 0.2 ng/mL.
(B) Sample flow diagram indicating the quality control measures applied to each sample, and the number of samples
passing the respective cut-offs per omics data stream.




30 31

Figure S2: Tissue ChIP-seq quality metrics.

- 32 (A) Boxplots showing the median total number of reads for AR (red), FOXA1 (blue) and H3K27ac (green) ChIP-seq, as
- 33
- 34
- (B) Boxplots indicating the percentage of aligned reads per ChIP factor.

well as ChIP-seq input (gray) samples.

35 (C) Scatter plot of phantom peak results, showing the normalized strand cross-correlation coefficient (NSC) and relative strand cross-correlation coefficient (RSC) scores for each ChIP-seq and input sample.
37 (D) Boxplot showing the number of peaks per ChIP-seq sample. Peak calling was performed over matched input control samples.
39 (E) Boxplots indicating the fraction of reads in peaks (FRiP) score per sample.
40





Correlation between tissue ChIP-seq samples:


4	1

42 Figure S3: Correlation between tissue ChIP-seq samples.

43Boxplots indicating the Pearson correlation of ChIP-seq samples based on peak occupancy. Both, pairwise44comparisons within the same ChIP-seq dataset (AR vs. AR, FOXA1 vs. FOXA1, H3K27ac vs. H3K27ac), and between45different datasets (AR vs. FOXA1, AR vs. H3K27ac, FOXA1 vs. H3K27ac) are shown. The corresponding correlation46matrix is shown in Fig. 2B.









0 z-score

B CNV at pre-enriched FOXA1 binding sites:



Correlation between FOXA1 ChIP-seq and CNV-seq data:



62

64

65

Ε

% of FOXA1 binding sites 9 00 00

63 Figure S5: Copy number variation at differential FOXA1 sites.

FOXA1 binding sites

Recurrent CNVs at differential FOXA1 binding sites:

20/1,430

Postenriched Recurrent CNVs

Yes No

n


24/475

Preenriched


(A) Boxplot showing the median copy number ratio at pre-enriched (left) and post-enriched (right) FOXA1 binding sites over all pre-treatment and post-treatment samples.


- 66 (B-C) Heatmap depicting segmented CNV data at pre-enriched (B) and post-enriched (C) FOXA1 binding sites in pre67 and post-treatment samples (columns). Differential FOXA1 sites are ordered per chromosome (rows) and heatmap
 68 color indicates copy number gains and losses (z-score).
- 69(D) Scatter plot showing the correlation between FOXA1 ChIP-seq data and CNV-seq data for paired pre-treatment and70post-treatment samples (n=15). Plotted is the normalized ChIP readcount difference (post vs. pre ENZ) against the71CNV ratio difference (post vs. pre ENZ) at all differential FOXA1 binding sites (n=1,905) per patient. CNV cut-offs of \pm 720.1 (dotted vertical lines) and mean Pearson correlation (R = 0.11; range: -0.02 0.26) are indicated. Differential73FOXA1 binding sites (dots) are colored based on their enrichment (pre-enriched vs. post-enriched) and recurrent CNV74events found in \geq 3 patients are highlighted.
- (E) Stacked bar plot indicating the fraction of differential FOXA1 sites that show recurrent CNVs shown in (D) with CNV
 ratio > 0.1 for post-enriched and < 0.1 for pre-enriched FOXA1 sites in 3 or more patients (pre: n=24/475, post: n=20/1,430).
- 78

A Occupancy of differential FOXA1 sites in all DARANA samples:



E Correlation of AR and H3K27ac ChIP-seq signals at differential and consensus FOXA1 binding sites in untreated tumors (n=87):






В

 $r_{VOJ} \operatorname{perform}_{10} r_{OJ} r_{O$

F Overlap between diff. FOXA1 sites and metARBS:




80	Figure S6: Cl	haracterization of differential FOXA1 sites.
81	(A)	Coverage heatmap showing occupancy of differential (pre-/post-enriched) and consensus FOXA1 peaks in all
82		generated pre- and post-treatment ChIP-seq samples. Heatmap color indicates region read counts (z-score) at pre-
83		enriched, post-enriched and consensus FOXA1 sites (rows) in the pre- and post-treatment AR (red), FOXA1 (blue)
84		and H3K27ac (green) ChIP-seq data streams (columns).
85	(B)	Boxplot showing normalized FOXA1 gene expression before and after 3 months of neoadjuvant ENZ treatment. ****,
86		<i>P</i> < 0.0001 (Mann-Whitney U-test).
87	(C-I	D) Representative tornado plots (top) and average density plots (bottom) visualizing H3K27ac ChIP-seq signal (in
88		FPKM) at pre-enriched (C) and post-enriched (D) FOXA1 binding sites in 3 patients (DAR24, DAR39, DAR52) before
89		and after ENZ treatment. Data are centered at FOXA1 peaks depicting a 10-kb (heatmaps) or 2.5-kb (density plots)
90		window around the peak center.
91	(E)	Scatter plots showing the correlation between AR and H3K27ac ChIP-seq signals at pre-enriched (top), post-enriched
92		(middle) and consensus (bottom) FOXA1 sites in treatment-naïve primary prostate tumors (n=87). Pearson correlations
93		for pre-enriched ($R = 0.54$), post-enriched ($R = 0.78$) and consensus ($R = 0.50$) FOXA1 sites are indicated.
94	(F)	Bar chart indicating the overlap between pre-enriched (left) and post-enriched (right) FOXA1 binding sites, and
95		previously identified (2) metastasis-specific AR binding sites (metARBS). ****, P < 0.0001 (Fisher's exact test).
96		

А

Top downregulated pathways upon ENZ treatment: G2M checkpoint Mitotic spindle Myc targets V2 Treatment I Pre I Post ____ 4 2 O Z-SCOre z-score z-score 0 2 -2 .4 В Top upregulated pathways upon ENZ treatment: TNFa via NFKb Epithelial-Mesenchymal transition INF-γ response Treatment I Pre I Post 2 2 0 z-score C r z-score z-score -2 4

Figure S7: Differential gene expression.


99	Heatmaps depicting differential gene expression of top downregulated (A) and top upregulated (B) pathways upon
100	ENZ treatment. Unsupervised hierarchical clustering of pre- and post-treatment RNA-seq samples is based on the
101	expression of genes that define the respective hallmark gene sets. Color scale indicates gene expression (z-score).
102	




108 per cluster and the color scale of the heatmap indicates gene expression (z-score).

Α

Example snapshots of H3K27ac ChIP-seq signal at the ARNTL locus:



- > 0.05 (Mann-Whitney U-test).
- 117(C) Boxplots depicting normalized CLOCK gene expression in ENZ non-responders (BCR \leq 6 months; n=8) and118responders (no BCR; n=29) in the pre- (left) and post-treatment (right) setting separately. ns, P > 0.05 (Mann-Whitney119U-test).




121

123 124

- 122 Figure S1
 - (A) Boxplot showing the number of FOXA1 peaks per ChIP-seq condition (Pre^{LNCaP}, Post^{LNCaP}, Res^{LNCaP-42D}). Peak calling

was performed over matched cell line input control samples.

125 (B) Venn diagram indicating the overlap of FOXA1 binding sites in all tested cell line conditions (Pre^{LNCaP}, Post^{LNCaP}, 126 Res^{LNCaP-42D}). For each condition, only peaks present in both replicates were included. The FOXA1 consensus cistrome 127 across conditions (n=35,602 sites) was used for genomic distribution (C) and motif enrichment (D) analyses. 128 (C) Pie chart showing the genomic distribution of consensus FOXA1 binding sites. 129 (D) Word cloud shows motif enrichment at consensus FOXA1 sites. The font size represents the z-score and colors 130 correspond to transcription factor families. 131 (E) Representative example snapshots of FOXA1 ChIP-seq signal at two pre-enriched (left) and two post-enriched (right) 132 FOXA1 binding sites. Per genomic location, the pre- and post-treatment FOXA1 ChIP-seg signal from one patient 133 (top), as well as the signal in all tested cell line models (bottom) is shown. For cell lines, the average of two biological 134 replicates is represented. Y-axis indicates ChIP-seq signal in FPKM. 135 (F) Correlation heatmap based on FOXA1 peak occupancy. Clustering of the samples is based on all called peaks and 136 represents Pearson correlations between individual ChIP-seq samples. The column color bars indicate the ChIP-seq 137 condition (Pre^{LNCaP}, Post^{LNCaP}, Res^{LNCaP-42D}) and replicate information (Rep1, 2). 138 (G) Principal component analysis (PCA) plot based on FOXA1 peak occupancy. Each dot represents a ChIP-seq sample 139 that is colored per condition (2 replicates per condition). 140





143	(A)	Boxplot showing the number of ARNTL peaks per ChIP-seq condition (Pre ^{LNCaP} , Post ^{LNCaP} , Res ^{LNCaP-42D}). Peak calling
144		was performed over matched cell line input control samples.
145	(B)	Representative example snapshots of ARNTL ChIP-seq signal at canonical circadian rhythm genes. The average of
146		two biological replicates is represented. Y-axis indicates ChIP-seq signal in FPKM.
147	(C)	Pie chart showing the genomic distribution of ARNTL consensus sites (shared across all conditions; n=1,515 sites).
148		The corresponding Venn diagram is shown in Fig. 6E.
149	(D)	Word cloud shows motif enrichment at ARNTL consensus sites (n=1,515). The font size represents the z-score and
150		colors correspond to transcription factor families. Since the human ARNTL motif is not part of the tested database, the
151		homologous mouse motif (Arntl) was included.
152	(E)	Representative example snapshots of ARNTL ChIP-seq signal at two post-enriched FOXA1 binding sites. Per genomic
153		location, the pre- and post-treatment FOXA1 ChIP-seq signal from one patient, as well as the ARNTL signal in all
154		tested cell line models (bottom) is shown. For cell lines, the average of two biological replicates is represented. Y-axis
155		indicates ChIP-seq signal in FPKM.
156	(F)	Correlation heatmap based on ARNTL peak occupancy. Clustering of the samples is based on all called peaks and
157		represents Pearson correlations between individual ChIP-seq samples. The column color bars indicate the ChIP-seq
158		condition (Pre ^{LNCaP} , Post ^{LNCaP} , Res ^{LNCaP-42D}) and replicate information (Rep1, 2).
159	(G)	Principal component analysis (PCA) plot based on ARNTL peak occupancy. Each dot represents a ChIP-seq sample
160		that is colored per condition (2 replicates each).
161		

162 Supplementary References

163

- Montgomery B, Tretiakova MS, Joshua AM, Gleave ME, Fleshner N, Bubley GJ, *et al.* Neoadjuvant Enzalutamide Prior to Prostatectomy. Clin Cancer Res **2017**;23(9):2169-76 doi
 10.1158/1078-0432.CCR-16-1357.
- 166 10.1158/1078-0432.CCR-16-1357.
 167 2. Pomerantz MM, Qiu X, Zhu Y, Takeda DY, Pan W, Baca SC, *et a*
- Pomerantz MM, Qiu X, Zhu Y, Takeda DY, Pan W, Baca SC, et al. Prostate cancer reactivates developmental epigenomic programs during metastatic progression. Nat Genet 2020;52(8):790-9 doi 10.1038/s41588-020-0664-8.
- Stelloo S, Nevedomskaya E, Kim Y, Schuurman K, Valle-Encinas E, Lobo J, *et al.* Integrative
 epigenetic taxonomy of primary prostate cancer. Nat Commun **2018**;9(1):4900 doi
 10.1038/s41467-018-07270-2.